Cymulate Reveals Next-level AI Automation for Threat Exposure Validation
The company introduces first-of-a-kind automated remediation to eliminate threat exposure, optimize controls and mitigate validated security gaps
Cymulate, the leader in threat exposure validation, today announced the next evolution of the company’s flagship security validation platform. As a pioneer and market leader for breach and attack simulation (BAS) and automated red teaming, Cymulate continues to innovate with automation and artificial intelligence (AI) to deliver the most advanced and easiest-to-use threat exposure validation on the market. At a time when attackers are deploying more advanced tactics than ever, the Cymulate Exposure Validation Platform leverages the power of AI to give every blue and red teamer the automation and accessibility to validate and remediate threat exposure and optimize security.
Exposure validation helps organizations go further than traditional solutions like BAS and automated penetration testing. By embracing the CTEM strategy, security teams can validate their exposure according to their defined threat scope, prioritize contextually according to their specific security strategy, and mobilize while continuously and automatically remediating gaps.
“Security leaders recognize that they need to rapidly address the most exploitable threats in a continuous fashion. Cymulate is bringing first-to-market innovation and automation in our Exposure Validation Platform so security teams can fix their biggest gaps and improve defensive posture before it’s too late,” said Avihai Ben-Yossef, Co-founder and CTO, Cymulate. “We’ve made technologies like attack simulation and automated red teaming easy to implement with actionable findings. Customers are seeing results that reduce noise, clarify decision making and increase the ROI of cyber defense investments.”
The Cymulate Exposure Validation Platform allows security teams to validate their controls alongside potential threats and response tactics, determining which threats are most risky and generating a remediation strategy that prioritizes those exposures first and automates control optimization. Innovative new features include:
- An AI-powered agent that guides blue teamers and red teamers to create the most impactful validation for their focus – from best practices to industry-specific threats to detailed attack chains from the latest threat intel
- Streamlined attack simulations that create easier assessments across the MITRE ATT&CK kill chain for all environments, including the most comprehensive library of cloud and Kubernetes attack scenarios
- A new attack scenario workbench designed to create comprehensive validation assessments from a library of more than one million attack actions or custom scenarios
- Modular and dynamic assessments that help test for new threats
A key aspect of the Cymulate Exposure Validation Platform is an elevation in the outcome that allows actionable and vendor-specific remediation. Security teams can use their existing stack to manually add optimization rules. Cymulate then automatically pushes these rules to the security controls and automates the entire remediation process.
“The Cymulate Exposure Validation Platform makes advanced security testing fast and easy. When it comes to building custom attack chains, it’s all right in front of you in one place. You can access the full Cymulate library or build your own attack actions,” said Mike Humbert, Cybersecurity Engineer at Cymulate customer Darling Ingredients Inc. “As you start to click and filter, you have the ability to refine what you’re testing, schedule the assessment and drill down to results.”
To learn more about the Cymulate Exposure Validation Platform, visit www.cymulate.com.
About Cymulate
Cymulate, the leader in security and exposure validation, provides the single source of truth for threat exposure and the actions required to close security gaps before attackers can exploit them. More than 1,000 customers worldwide rely on the Cymulate platform to baseline their security posture and strengthen cyber resilience with continuous discovery, validation, prioritization, and guided remediation of security weaknesses. Cymulate automates advanced offensive security testing to validate controls, threats, and attack paths. As an open platform, Cymulate integrates with existing security and IT infrastructure and drives the workflows of the exposure management process. For more information, visit www.cymulate.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218739287/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom